LUTATHERA®

Lutetium (177Lu) oxodotreotide

The GEPNETs Hunter

Indication: LUTATHERA® is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEPNETs) in adults.

EFFICACY

82% risk reduction of progression or death

SAFETY

Established in phases 1, 2 & 3